The pharmacotherapy of schizophrenia is currently dominated by atypical antipsychotics that primarily target dopaminergic signalling, the dysregulation of which has long been considered to have a ...

Developed by Karuna Therapeutics, recently acquired by Bristol Myers Squibb, Cobenfy diverges from the industry’s dopamine-dominated approach, targeting muscarinic acetylcholine receptors instead.